



## General Meeting and Board of Directors of May 28, 2020

**Paris, France. May 28, 2020** – 6.00 PM CEST– Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, held its General Meeting today in a closed session, which adopted all the proposed resolutions.

The General Meeting has approved the renewal of Mr. Bernard Gilly, Mr. Lloyd Diamond and Mr. Robert Ten Hoedt as Directors for three years, and the renewal of Kreos Capital as Observer also for three years.

The Board of Directors meeting has renewed the term of office of Mr. Bernard Gilly as Chairman of the Board for three years.

The Board of Directors of Pixium Vision is composed of the following members:

- Mr Bernard Gilly, Chairman of the Board
  - Mr Lloyd Diamond, Chief Executive Officer and Director
  - BPIfrance Participations, represented by Mrs Olivia Le Proux de la Rivière, Director
  - Sofinnova Partners, represented by Mr Gérard Hascoët, Director
  - Mrs Marie Meynadier, Independent Director
  - Robert J. W. Ten Hoedt, Independent Director
- 
- Kreos Capital V (Expert Fund) LTD, represented by Mr Aris Constantidines, Observer

### Contacts

#### **Pixium Vision**

Didier Laurens  
Chief Financial Officer

[investors@pixium-vision.com](mailto:investors@pixium-vision.com)

+33 1 76 21 47 68

#### **Media relations**

##### **LifeSci Advisors**

Sophie Baumont

[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)

+33 6 27 74 74 49

#### **Investor relation**

##### **LifeSci Advisors**

Guillaume van Renterghem

[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

+33 6 69 99 37 83

**Pixium Vision** is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information:  <http://www.pixium-vision.com/fr>

Follow us on  @PixiumVision;  [www.facebook.com/pixiumvision](http://www.facebook.com/pixiumvision)

**Linked**  [www.linkedin.com/company/pixium-vision](http://www.linkedin.com/company/pixium-vision)

**PIX**  
**LISTED**  
**EURONEXT**



Pixium Vision is listed on Euronext Growth Paris.  
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index